Curaleaf Holdings, Inc. splits its revenue into 4 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Domestic at $1.1 billion, 86% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
1,268
|
1,334
|
1,347
|
1,275
|
1,196
|
627
|
| Cannabis |
—
|
—
|
—
|
—
|
—
|
1,207
+106.0%
share 100.9%
|
586
share 93.6%
|
| Domestic |
—
|
1,096
-10.8%
share 86.4%
|
1,229
-4.4%
share 92.1%
|
1,286
+3.6%
share 95.5%
|
1,241
share 97.3%
|
—
|
—
|
| International |
—
|
172
+63.4%
share 13.6%
|
106
+73.0%
share 7.9%
|
61
+77.2%
share 4.5%
|
34
share 2.7%
|
—
|
—
|
| Non Cannabis |
—
|
—
|
—
|
—
|
—
|
2
-94.3%
share 0.2%
|
40
share 6.4%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- CURLF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Stamford, CT
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1756770
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
- Aurora Cannabis Inc ACB
Source: SEC EDGAR filings. This is company-reported data, not investment advice.